In order for a tunable anti-VEGF therapy for the treatment of wet AMD to be successful, it is likely that free VEGF levels will need to be tightly regulated so that they reach a steady state concentration wherein CNV formation is prevented, but retinal atrophy is not accelerated. This evidence concerns the gene VEGFA and wet macular degeneration.